ReAlta Life Sciences announces FDA orphan drug designation for PIC1 to treat hypoxic-ischemic encephalopathy

This article was originally published here

“There is an urgent need for new therapeutic options to treat hypoxic-ischemic encephalopathy, a devastating condition that profoundly impacts newborns and their families,” said Ulrich Thienel, M.D., Ph.D.,

The post ReAlta Life Sciences announces FDA orphan drug designation for PIC1 to treat hypoxic-ischemic encephalopathy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply